Amplia Therapeutics Limited (ASX:ATX) Share Price Rises 3.57% as Stock Trades Near Session High

Anjali Anand

13 August 2026 09:36 PM AEST

Amplia Therapeutics Limited (ASX:ATX) Share Price Rises 3.57% as Stock Trades Near Session High

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Amplia Therapeutics Limited (ASX:ATX) shares closed higher at $0.145 after gaining 3.571% during the session.
The stock traded within a daily range of $0.140 to $0.150.
Trading Volume reached 396,686 shares during the session.
Market capitalisation stood at $71.86M based on the latest provided figures.
The share price remained within its 52-week range of $0.100 to $0.275.

Overview

Amplia Therapeutics Limited (ASX:ATX) is listed on the Australian Securities Exchange and operates within the Pharmaceuticals, Biotechnology & Life Sciences industry group. This article provides an educational summary of the company’s latest available share price activity and market statistics based on the provided data.

The article focuses on trading information, including daily price movement, volume, market capitalisation, share structure and historical price range. It is intended to provide a factual overview of market data and does not represent financial advice or a recommendation regarding the company’s shares.

Share Price Movement

Shares of Amplia Therapeutics Limited (ASX:ATX) closed at $0.145, representing an increase of $0.004 or 3.571% compared with the previous close of $0.140. During the trading session, the stock moved between an intraday high of $0.150 and an intraday low of $0.140.

The difference between the day’s highest and lowest prices reflects the trading range observed during the session. The share price ended at the upper end of its daily range, with the available data showing the stock traded between $0.140 and $0.150.

The 52-week trading range for Amplia Therapeutics Limited was recorded between $0.100 and $0.275. This range represents the highest and lowest prices reached by the stock over the previous 12-month period and provides historical context for the latest share price level.

Trading Volume and Market Capitalisation

Amplia Therapeutics Limited recorded trading volume of 396,686 shares during the session. Trading volume indicates the number of shares exchanged between buyers and sellers and is commonly considered alongside price movements to understand the level of market activity during a trading period.

The average volume for the stock was recorded at 1,400,572 shares. Comparing daily volume with average volume provides a reference point for assessing whether the latest trading activity was above or below the stated average level.

The company’s Market Capitalisation was $71.86M based on the latest provided market data. Market capitalisation represents the total Market Value of a company’s Issued Shares and is calculated using the share price and the number of shares on issue.

Share Information and Trading Details

Amplia Therapeutics Limited has 513,312,014 shares on issue, with its share structure classified as ordinary fully paid shares. The company was listed on the Australian Securities Exchange on 23 December 2013.

The bid and offer range was recorded between $0.145 and $0.150, reflecting the available buying and selling price levels during the trading session.

The daily trading range of $0.140 to $0.150 highlights the movement of the stock throughout the session. Such trading indicators provide a snapshot of market activity for a specific period and should be considered alongside broader company and market information.

Industry Group and Market Context

Amplia Therapeutics Limited is categorised within the Pharmaceuticals, Biotechnology & Life Sciences industry group. Companies in this industry group generally operate across pharmaceutical development, biotechnology activities and related life sciences areas.

Individual share price movements can be influenced by various factors, including market participation and company-specific developments. A single Trading session reflects short-term market activity and represents only one part of a company’s overall trading history.

Conclusion

In summary, Amplia Therapeutics Limited (ASX:ATX) shares closed at $0.145 after recording a gain of 3.571% during the latest trading session. The stock traded between $0.140 and $0.150, with trading volume of 396,686 shares and a market capitalisation of $71.86M. The available market statistics, including the 52-week range, shares on issue and trading activity, provide an educational overview of the company’s latest market position based on the supplied information.

Frequently Asked Questions (FAQs)

FAQs

Q: What was the closing share price of Amplia Therapeutics Limited (ASX:ATX)?

A:Amplia Therapeutics Limited (ASX:ATX) closed at $0.145 based on the latest provided market data.

Q: How much did ATX shares increase during the session?

A:The share price increased by $0.004, representing a gain of 3.571% from the previous close of $0.140.

Q: What was the trading volume for Amplia Therapeutics Limited?

A:The trading volume for the session was 396,686 shares.

Q: What is the market capitalisation of Amplia Therapeutics Limited?

A:The company’s market capitalisation was recorded at $71.86M based on the provided figures.

Q: What was the 52-week trading range for ASX:ATX?

A:The 52-week trading range for Amplia Therapeutics Limited was between $0.100 and $0.275.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.